US equities
|
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Sonnet BioTherapeutics Holdings, Inc. - Common Stock
(NQ:
SONN
)
1.260
UNCHANGED
Last Price
Updated: 4:00 PM EST, Dec 2, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sonnet BioTherapeutics Holdings, Inc. - Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Why Is F45 Training Holdings Down By 56%? Here Are 28 Stocks Moving In Wednesday's Pre-Market Session
↗
July 27, 2022
Gainers Dave Inc. (NASDAQ: DAVE) rose 56.9% to $0.9826 in pre-market trading. Dave is expected to release its second quarter 2022 financial results on Thursday, August 11, 2022.
Via
Benzinga
Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy
July 22, 2022
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy
July 22, 2022
PRINCETON, NJ / ACCESSWIRE / July 22, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that a Phase...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers
July 21, 2022
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers
July 21, 2022
PRINCETON, NJ / ACCESSWIRE / July 21, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that a second...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
44 Stocks Moving In Friday's Mid-Day Session
↗
June 10, 2022
Gainers Cogent Biosciences, Inc. (NASDAQ: COGT) shares jumped 77% to $8.79 after the company reported initial data from its ongoing Phase 2 APEX clinical trial.
Via
Benzinga
Sonnet Shares Surge As FDA Clears Its First Human Trial For Solid Tumor Candidate
↗
March 16, 2022
Via
Benzinga
91 Biggest Movers From Friday
↗
June 13, 2022
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.
Via
Benzinga
69 Biggest Movers From Yesterday
↗
June 10, 2022
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares climbed 189.9% to close at $1.12 on Thursday.
Via
Benzinga
Mid-Afternoon Market Update: Skillsoft Falls After Q1 Results; Applied UV Shares Spike Higher
↗
June 09, 2022
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 1% on Thursday.
Via
Benzinga
Mid-Day Market Update: Dow Drops 150 Points; Bluejay Diagnostics Shares Jump
↗
June 09, 2022
U.S. stocks traded lower midway through trading, with the Dow Jones dropping 150 points on Thursday.
Via
Benzinga
36 Stocks Moving In Thursday's Mid-Day Session
↗
June 09, 2022
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) jumped 65% to $0.6382.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
June 09, 2022
Via
Benzinga
Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition
June 09, 2022
PRINCETON, NJ / ACCESSWIRE / June 9, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs,...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum
June 02, 2022
PRINCETON, NJ / ACCESSWIRE / June 2, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs,...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update
May 10, 2022
- IND for SON-1010 cleared by FDA with first patient dosed in trial for advanced solid tumors - SON-080 on track to begin clinical studies by mid-2022 - Preclinical data for SON-1010, SON-1210, and...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
↗
April 13, 2022
Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday!
Via
InvestorPlace
Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors
April 13, 2022
PRINCETON, NJ / ACCESSWIRE / April 13, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that dosing has...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual Meeting
April 08, 2022
PRINCETON, NJ / ACCESSWIRE / April 8, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that data from...
From
Sonnet BioTherapeutics, Inc.
Via
AccessWire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
↗
April 08, 2022
Good morning, trader! Get ready for another busy day of trading with our breakdown of the biggest pre-market stock movers for Friday!
Via
InvestorPlace
16 Stocks Moving in Friday's Pre-Market Session
↗
April 08, 2022
Gainers Biofrontera Inc. (NASDAQ: BFRI) rose 34.5% to $5.44 in pre-market trading. ENDRA Life Sciences Inc. (NASDAQ: NDRA) rose 31.9% to $0.5891 in pre-market trading after...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
March 18, 2022
Gainers Aesthetic Medical Intl (NASDAQ:AIH) shares increased by 27.8% to $1.77 during Friday's regular session. The current volume of 149.1K shares is 551.4% of...
Via
Benzinga
58 Biggest Movers From Friday
↗
March 21, 2022
Gainers BEST Inc. (NYSE: BEST) shares gained 73.6% to close at $1.00. DiDi Global Inc. (NYSE: DIDI) shares jumped 59.8% to settle at $4.09 on Friday. Zhihu Inc. (NYSE: ZH)...
Via
Benzinga
45 Stocks Moving In Friday's Mid-Day Session
↗
March 18, 2022
Gainers Grom Social Enterprises, Inc. (NASDAQ: GROM) jumped 62.4% to $1.5500. DiDi Global Inc. (NYSE: DIDI) shares climbed 46% to $3.73. Kidpik Corp. (NASDAQ: PIK) shares...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
March 18, 2022
Gainers Sunshine Biopharma (NASDAQ:SBFM) stock increased by 15.5% to $3.5 during Friday's pre-market session. The company's market cap stands at $15.6 million....
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
↗
March 18, 2022
Good morning, trader! Let's start off the final day of the workweek right with a breakdown of the biggest pre-market stock movers for Friday!
Via
InvestorPlace
25 Stocks Moving in Friday's Pre-Market Session
↗
March 18, 2022
Gainers Grom Social Enterprises, Inc. (NASDAQ: GROM) rose 60.5% to $1.53 in pre-market trading. StoneCo Ltd. (NASDAQ: STNE) shares rose 23.7% to $11.90 in pre-market trading...
Via
Benzinga
22 Stocks Moving in Thursday's Pre-Market Session
↗
March 17, 2022
Gainers TD Holdings, Inc. (NASDAQ: GLG) rose 81.2% to $0.43 in pre-market trading after the company reported FY21 results. Orphazyme A/S (NASDAQ: ORPH) shares rose 35.1% to $0....
Via
Benzinga
80 Biggest Movers From Yesterday
↗
March 17, 2022
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares gained 86.7% to close at $0.5150 on Wednesday after the company announced FDA clearance of its IND for SON-...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
March 16, 2022
Gainers Sonnet BioTherapeutics (NASDAQ:SONN) shares rose 114.0% to $0.59 during Wednesday's regular session. As of 13:30 EST, this security is trading at a volume of...
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
